Allergy Therapeutics: On the starting blocks towards key data expected in 2023
The next 12-18 months will be key for Allergy Therapeutics, with the base European commercial business set to return to growth, whilst important pipeline readouts could propel the company closer to US market entry. In Europe, temporary headwinds impacted growth in Germany, Allergy Therapeutics’ largest market; these should abate, enabling a return to near double-digit revenue growth. Meanwhile, clinical trials for both VLP Peanut and Grass MATA MPL are set to initiate this year for data in summer and Q4 2023, respectively. These differentiated assets underpin future entry into the commercially important US market and could transform the company in the mid-term. Cash of £20.5m (FY21: £40.3m) has been boosted by £7m in equity and £10m in debt, enabling preparations to advance both of these pipeline programmes beyond planned trials. Our updated valuation is £327.7m, or 48.3p/share.Allergy Therapeutics is a pharmaceutical group focused on allergy vaccination. Co. mainly sell its products in European countries and its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, as well as a peanut allergy vaccine in preclinical development. Co. sells a range of aluminium-free allergy vaccines and diagnostics. Co. sells both injectable and sublingual (oral) formats. The commonly prescribed are those for the treatment of pollen related allergies, particularly for allergies to grasses, weeds and trees. Co.'s vaccines trade under various brand names depending on the market, e.g. Pollinex Quattro, Polligoid and TA Graser Top.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.